Patents by Inventor Jeff Babon

Jeff Babon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of cytokine-induced SH2 protein in NK cells
    Patent number: 11104735
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: August 31, 2021
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson, Jeff Babon, Tatiana Kolesnik
  • INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS
    Publication number: 20210171636
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 10, 2021
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson, Jeff Babon, Tatiana Kolesnik
  • Inhibition of cytokine-induced SH2 protein in NK cells
    Patent number: 10975149
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 13, 2021
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson, Jeff Babon, Tatiana Kolesnik
  • Inhibition of Cytokine-Induced SH2 Protein in NK Cells
    Publication number: 20180298101
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
    Type: Application
    Filed: December 16, 2016
    Publication date: October 18, 2018
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson, Jeff Babon, Tatiana Kolesnik
  • Screening method for substance binding to merozoite surface protein-1/42
    Publication number: 20070003987
    Abstract: Disclosed is a method of screening a test substance for possession of binding activity for possession of binding activity for MSP42 or a fragment thereof, the method comprising the steps of: combining or contacting, in any order, (i) a molecule comprising MSP142 or a fragment thereof, (ii) the test substance, and (iii) a comparison substance known to have binding activity for MSP142 or a fragment thereof; and determining the presence and/or amount, if any, of comparison substance and/or test substance bound of the MSP142 or fragment thereof.
    Type: Application
    Filed: June 18, 2004
    Publication date: January 4, 2007
    Applicants: MEDICAL RESEARCH COUNCIL, KING'S COLLEGE LONDON
    Inventors: Anton Dluzewski, Anthony Holder, Berry Birdsall, Jeff Babon, Stephen Martin, William Morgan, James Feeney, Michael Blackman, Suzanne Fleck, Barbara Saxty
  • Detection of mismatches by resolvase cleavage using a magnetic bead support
    Patent number: 5851770
    Abstract: Disclosed is a method for detecting one or more mismatches between a first and a second nucleic acid, the first and second nucleic acids being capable of preferentially hybridizing.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: December 22, 1998
    Assignee: Variagenics, Inc.
    Inventors: Jeff Babon, Rima Youil, Jay Stoerker, Anne Huff, Richard G. H. Cotton